

**Phenotypic and Functional Characterisation of Innate and
Adaptive Immune Responses after Mucosal Vaccination.**

By
Lindsay Jennifer Hall

This dissertation is submitted for the degree of Doctor of Philosophy

July 2007



**Sidney Sussex College
University of Cambridge**

Abstract

The successful development of mucosal vaccines is still impeded by our lack of understanding of how the mucosal immune system regulates antigen-specific responses. As most pathogens interact with or invade their host through a mucosal surface we may learn more about mucosal immunity by investigating the interaction of pathogens and their products with host factors and cells at mucosal surfaces. Here I examine the properties of a live *Salmonella*-based vaccine and a mucosal adjuvant based on a bacterial protein. Initially I examined the immunogenicity of the *M. tuberculosis* fusion antigen Ag85B-ESAT6 using a number of different mucosal vaccination strategies. These strategies included (i) intranasal immunisation with Ag85B-ESAT6 protein with and without Heat Labile toxin as an adjuvant (ii) oral immunisation with *Salmonella enterica* Typhimurium expressing Ag85B-ESAT6 from *in vivo* inducible or constitutive promoters (with and without intranasal boosts). Mice immunised with the various vaccine candidates were found to have significant anti-Ag85B-ESAT6 serum and mucosal antibody titres as well as strong T_H1 type cytokine responses, with IFN- γ levels particularly high. Intranasal boosting served to further enhance these immune responses. Following vaccination with the constitutive *Salmonella* vector, mice challenged with *M. tuberculosis* were found to have significantly reduced CFU in the liver when compared to non-vaccinated animals. Mice primed with *Salmonella* and then boosted intranasally with Ag85B-ESAT6/LTK63 led to a significant increase in protection, equivalent to that observed in mice vaccinated with BCG.

The nasal route for vaccination offers some important opportunities for the prophylaxis of many diseases, however the description of immune responses involved early after intranasal administration of antigen have not been clearly established. In a separate study, flow cytometry and confocal microscopy were used to examine the frequencies and localisation of innate immune cells, their activation status, as well as the expression of cell adhesion molecules following intranasal immunisation. I found striking differences between the cell surface phenotype of leukocytes and their pattern of distribution in the tissues examined at all time points tested after immunisation. Following on from these results one particular cell type was examined in more depth to determine its role in adaptive immune responses.

Acknowledgements

Firstly, I would like to thank my supervisor Professor Gordon Dougan for giving me the opportunity to complete this PhD, and for his support and guidance. I would also like to thank Dr Simon Clare for being there with his vast technical experience, ideas and insights. A special thanks to Del and Chris for their willingness to give their time, expertise, and enthusiasm.

A massive thank you to everyone in Teams 15 and 100 for helping me with all those important little things, be it just ‘banter’, and especially to the ladies for all your support and encouragement. Thanks to TJ McKindley (a.k.a. Trevelyan) for his clear guidance with the statistics.

I would also like to thank everyone involved in the MUVAPRED grant (Mucosal Vaccines against poverty related diseases) for the opportunity to work in vaccine development, and to be part of a program that could really make a difference.

Thanks to my friends, especially Emma, Emma and Stephanie, who believed that I could do it, and helped me by just listening and talking about things other than science. The Chums – you know who you are, thanks for providing me with those crazy moments!

My family obviously deserve a big thank you for always believing I would get there, mum, dad, Brendan and Eilidh, and especially to dad for giving me the drive to have that Indiana Jones moment!

Thanks to Danny for helping me through all of this, be it through reading and checking, or just providing support and distraction when I needed them most.

Finally I would like to dedicate this PhD thesis to my granddad Dan, he always thought I could do it, and I’d like to think he would be very proud.

Declaration

This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except where specifically indicated in the text.

Help and guidance with the molecular cloning of *Salmonella* vaccine strains was provided by Dr D Pickard and Dr M Abd E L Ghany (Wellcome Trust Sanger Institute). Dr S Clare, also at the Wellcome Trust Sanger Institute, assisted the author in performing tissue collection from experimental animals and performed immunisations and animal procedures during the studies. In addition Dr Clare provided assistance with sample processing for fluorescence-assisted cell sorting on some sample days when the author was engaged in processing tissues for viable counts in these experiments.

All other immunisations, tissue collections, tissue processing (including cutting of frozen sections and immunostaining) were performed by the author.

Dr Jes Dietrich (Statens Serum Instiut, Denmark) performed the aerosol *M. tuberculosis* challenge experiments following vaccination with the recombinant constitutive *Salmonella* vaccine strain in their category 3 animal facilities.

Lindsay Jennifer Hall

July, 2007

Table of contents

Abstract	2
Acknowledgements	3
Declaration	4
Table of contents	5
List of tables	12
List of figures	13
Abbreviations	16
1 Introduction	19
1.1 <i>Mycobacterium tuberculosis</i>	19
1.1.1 General features.....	19
1.1.2 History.....	19
1.1.3 Epidemiology	20
1.1.4 General features of pathogenesis.....	22
1.2 Current vaccines against <i>M. tuberculosis</i>	27
1.2.1 Bacille Calmette-Guérin (BCG) vaccine.....	27
1.3 New tuberculosis vaccines	31
1.3.1 Recombinant BCG vaccines	32
1.3.2 Live mycobacterial vaccines	33
1.3.3 Non-mycobacterial vaccine vectors	34
1.3.4 DNA vaccines	35
1.3.5 Subunit vaccines.....	36
1.3.6 <i>M. tuberculosis</i> vaccine antigens	37
1.3.6.1 Antigen 85B	37
1.3.6.2 Early Secreted Antigenic Target-6.....	38
1.4 The mucosal immune system	39
1.4.1 Mucosal immunisation	41
1.4.2 Intranasal immunisation	41
1.4.3 The mucosal adjuvants LT and LTK63.....	43
1.4.4 Nasal Associated Lymphoid Tissue	44
1.4.4.1 General features.....	44
1.4.4.2 Structure of the NALT	44

1.4.4.3	Function of the NALT.....	47
1.4.4.4	Waldeyer's ring.....	51
1.4.5	Gut Associated Lymphoid Tissue.....	53
1.5	Live recombinant bacterial vaccines.....	56
1.5.1	Live, attenuated <i>Salmonella</i> vaccines and vectors.....	56
1.5.1.1	<i>Salmonella</i> pathogenesis.....	56
1.5.1.2	Immune response to infection with <i>Salmonella</i>	57
1.5.1.3	<i>Salmonella</i> as vaccine vectors.....	57
1.5.1.3.1	<i>S. Typhi</i> vaccine vectors.....	58
1.5.1.3.2	<i>S. Typhimurium</i> vaccine vectors.....	58
1.5.1.3.3	Immune responses generated after immunisation with <i>Salmonella</i> vectors.....	59
1.6	Hypothesis.....	60
1.7	Aims of this thesis.....	60
2	Materials and Methods.....	61
2.1	Materials.....	61
2.1.1	Reagents.....	61
2.1.2	Bacterial strains.....	61
2.1.3	Plasmid vectors.....	62
2.1.4	Oligonucleotide primers.....	62
2.1.5	Proteins for immunisations.....	63
2.1.6	ELISA antibodies.....	63
2.1.7	Immunofluorescence antibodies.....	63
2.1.8	Antibodies for FACS.....	64
2.1.9	Mice.....	64
2.2	Methods.....	64
2.2.1	Bacterial growth conditions.....	64
2.2.2	Animal methods.....	65
2.2.2.1	Preparation for inoculation/immunisation.....	65
2.2.2.1.1	Oral.....	65
2.2.2.1.2	Intranasal.....	66
2.2.2.1.3	Intraperitoneal.....	66
2.2.2.1.4	Intravenous.....	66
2.2.2.1.5	BCG immunisation.....	66

2.2.2.2	Experimental <i>M. tuberculosis</i> infections.....	66
2.2.2.3	Determination of pathogen burden.....	67
2.2.2.4	Natural Killer Cells (NKC) depletion	67
2.2.3	Molecular Methods	67
2.2.3.1	Plasmid DNA extraction	67
2.2.3.2	Agarose gel electrophoresis	67
2.2.3.3	DNA digestion	68
2.2.3.4	DNA ligation.....	68
2.2.3.5	Oligonucleotides	69
2.2.3.6	Polymerase chain reaction (PCR)	69
2.2.3.6.1	Characterisation of PCR products.....	70
2.2.3.7	Precipitation of DNA	70
2.2.3.8	DNA sequencing.....	71
2.2.3.9	Preparation of electrocompetent cells	71
2.2.3.10	Electroporation.....	71
2.2.3.11	Identification of bacteria	72
2.2.3.12	Red Recombinase “one step” mutagenesis	72
2.2.3.13	Transduction of <i>Salmonella</i> with P22 phage	73
2.2.4	ELISA methods.....	74
2.2.4.1	ELISA for total Ig, IgG and IgG subclasses in mouse sera (General ELISA protocol).....	74
2.2.4.2	ELISA for IgG2b, IgG3, IgE, IgA and IgM in mouse sera.....	74
2.2.4.3	ELISA for IgA in sera and lung and nasal washes.....	75
2.2.5	Measurement of cellular responses	75
2.2.5.1	Isolation of lymphocytes	75
2.2.5.2	T-cell cytokine assay using Cytokine Bead Analysis (CBA)	75
2.2.5.3	Lymphocyte preparation for FACS.....	76
2.2.6	Protein overexpression	76
2.2.6.1	Protein gel separation	76
2.2.6.2	Western blot analysis	77
2.2.6.3	Coomassie blue stain.....	77
2.2.6.4	Colony blot analysis.....	77
2.2.6.5	Opti-4CN stain (Bio-Rad).....	78
2.3	Tissue staining methods	78

2.3.1	Sectioning.....	78
2.3.1.1	NALT removal.....	78
2.3.1.2	Frozen sectioning.....	79
2.3.2	Immunofluorescent staining.....	79
2.3.2.1	Single immunofluorescent staining.....	79
2.3.2.2	Double or triple immunofluorescent staining.....	79
2.3.3	Histology.....	80
2.4	Statistical analysis.....	80
3	Immunogenicity of the tuberculosis fusion antigen, Ag85B-ESAT6, after an intranasal prime-boost regimen.....	81
3.1	Introduction.....	81
3.1.1	The tuberculosis fusion antigen, Ag85B-ESAT6.....	81
3.1.2	Intranasal immunisation and <i>M. tuberculosis</i>	83
3.2	Results.....	84
3.2.1	An intranasal prime-boost immunisation regimen with Ag85B-ESAT6 induces serum Ig.....	84
3.2.2	IgG1:IgG2a ratios after intranasal administration of Ag85B-ESAT6 and mucosal adjuvants.....	88
3.2.3	The fusion protein plus LT induces significant serum IgA, and mucosal IgA in lung and nasal washes following immunisation.....	89
3.2.4	Strong pro-inflammatory cytokine responses are induced following immunisation.....	90
3.3	Discussion.....	95
4	Characterisation of innate immune responses shortly after intranasal immunisation of model antigens.....	100
4.1	General introduction.....	100
4.1.1	Technical Note.....	105
4.2	Identification of cell populations early after intranasal immunisation.....	105
4.2.1	Introduction.....	105
4.2.2	Results.....	107
4.2.2.1	Percentage, distribution and activation status of NALT and CLN innate cell populations after intranasal immunisation.....	107
4.2.2.1.1	Dendritic Cells.....	111
4.2.2.1.1.1	5 hour time-point.....	113

4.2.2.1.1.2	24 hour time-point.....	113
4.2.2.1.1.3	72 hour time-point.....	114
4.2.2.1.2	Macrophages	115
4.2.2.1.2.1	5 hour time-point.....	117
4.2.2.1.2.2	24 hour time-point.....	117
4.2.2.1.2.3	72 hour time-point.....	118
4.2.2.1.3	Natural Killer Cells	119
4.2.2.1.3.1	5 hour time-point.....	121
4.2.2.1.3.2	24 hour time-point.....	121
4.2.2.1.3.3	72 hour time-point.....	121
4.2.2.1.4	Neutrophils	122
4.2.2.1.4.1	5 hour time-point.....	124
4.2.2.1.4.2	24 hour time-point.....	124
4.2.2.1.4.3	72 hour time-point.....	124
4.2.3	Discussion	131
4.2.3.1	5 hour time-point.....	131
4.2.3.2	24 hour time-point.....	133
4.2.3.3	72 hour time-point.....	135
4.2.3.4	Summary	136
4.3	Cell adhesion molecule expression early after intranasal immunisation ...	137
4.3.1	Introduction	137
4.3.1.1	Leukocyte trafficking and cell adhesion molecules	137
4.3.1.2	Cell adhesion molecule expression in the NALT and CLN.....	138
4.3.2	Results	139
4.3.2.1	Intranasal immunisation increases both expression and distribution of cell adhesion molecules at early time-points in the NALT and CLN.....	139
4.3.3	Discussion	149
4.4	Germinal centre formation early after intranasal immunisation	153
4.4.1	Introduction	153
4.4.2	Results	153
4.4.3	Discussion	156
4.5	Summary discussion.....	157
5	Natural killer cell depletion influences antigen specific cytokine and antibody responses after intranasal immunisation	160

5.1	Introduction	160
5.2	Results	163
5.2.1	Anti-Asialo GM1 treatment successfully depletes Balb/c mice of NKC.....	163
5.2.2	<i>In vivo</i> depletion of NKC affects induction of antigen-specific cytokine responses	167
5.2.3	Mice depleted of NKC have reduced antigen-specific antibody responses	170
5.3	Discussion	176
6	Live recombinant <i>Salmonella</i> vaccine candidates expressing the tuberculosis fusion antigen, Ag85B-ESAT6	181
6.1	General introduction.....	181
6.1.1	Live vector vaccines.....	181
6.1.2	<i>Salmonella</i> as vaccine vectors.....	184
6.2	Mucosally delivered live <i>Salmonella</i> , <i>in vivo</i> inducible, vector vaccines elicit significant immune responses against the tuberculosis fusion antigen, Ag85B-ESAT6.....	187
6.2.1	Introduction	187
6.2.2	Results	189
6.2.2.1	Construction of recombinant <i>Salmonella</i> vaccine strains and <i>in vitro</i> expression of Ag85B-ESAT6.....	189
6.2.2.2	Intragastric priming with recombinant SL3216 strains plus an intranasal Ag85B-ESAT6 boost and Ig responses	194
6.2.2.3	IgG1/IgG2a profile after recombinant <i>Salmonella</i> immunisation..	196
6.2.2.4	Intragastric priming with recombinant SL3216 strains plus an intranasal Ag85B-ESAT6 boost and cytokine responses.....	197
6.2.3	Discussion	200
6.3	A recombinant attenuated <i>S. Typhimurium</i> vaccine encoding the <i>M. tuberculosis</i> antigen, Ag85B-ESAT6, confers potent specific immune responses and induces significant reduction of bacterial colonisation of mice.	204
6.3.1	Introduction	204
6.3.2	Results	205
6.3.2.1	Construction of recombinant <i>Salmonella</i> vaccine strain and <i>in vitro</i> expression of Ag85B-ESAT6.....	205

6.3.2.2	Humoral immunogenicity of the oral recombinant <i>Salmonella</i> priming-intranasal protein boost vaccine regimen.....	208
6.3.2.2.1	Serum IgG antibody responses.....	211
6.3.2.2.2	IgG sub-class responses	213
6.3.2.2.3	Serum IgA responses.....	215
6.3.2.2.4	Mucosal immune responses.	217
6.3.2.3	Evaluation of cytokine responses after recombinant <i>Salmonella</i> vaccination	219
6.3.2.4	Protective efficacy of the recombinant <i>Salmonella</i> vaccine candidate.....	224
6.3.3	Discussion	226
7	Final discussion.....	231
8	Appendix.....	237
	References	261

List of tables

Table 2.1: Bacterial strains used during study	61
Table 2.2: Plasmid vectors used during study	62
Table 2.3: Details of primers used during study	62
Table 2.4: Proteins used in immunisations.....	63
Table 2.5: Antibodies used for ELISAs	63
Table 2.6: Antibodies for Immunofluorescence staining	63
Table 2.7: Antibodies for FACS analysis.....	64
Table 2.8: PCR Mixture for Platinum SuperMix (Invitrogen).....	70
Table 3.1: Ag85B-ESAT6 prime-boost immunisation regimen	84
Table 3.2: Ag85B-ESAT6 specific mucosal IgA responses after i.n. immunisation...89	
Table 3.3: Ag85B-ESAT6 cytokine responses in i.n. immunised mice.....	91
Table 4.1: Surface phenotype of isolated cells from NALT and CLN 5, 24 and 72 hours after intranasal immunisation.	110
Table 4.2: Cell Adhesion Molecules and Their Receptors.....	138
Table 6.1: Current live attenuated bacterial licensed vaccines	182
Table 6.2: Recombinant bacterial vector vaccine candidates	183
Table 6.3: Characteristics of live vaccines developed against typhoid fever.....	186
Table 6.4: Recombinant SL3261 immunisation regimen	194
Table 6.5: Recombinant <i>Salmonella</i> prime-boost immunisation schedule	209
Table 8.1: Activation marker expression on NALT and CLN innate immune cells from immunised Balb/c mice.	247

List of figures

Figure 1.1: Tuberculosis incidence rates 2005.....	20
Figure 1.2: Main features of tuberculosis: from infection to host defence.	23
Figure 1.3: Antigen processing/presentation pathways and activation of different T-cell subsets.....	26
Figure 1.4: Events that might lead to failure of BCG in developing countries.....	28
Figure 1.5: BCG historical genealogy incorporating genetic differences previously noted and newly detected genetic deletions.	30
Figure 1.6: Different tuberculosis vaccination strategies.....	31
Figure 1.7: Tuberculosis vaccines currently undergoing screening.....	32
Figure 1.8: The CMIS	40
Figure 1.9: Schematic representation of compartments and cellular composition of NALT.	46
Figure 1.10: Diagram of a lymph node	50
Figure 1.11: Pharyngeal lymphoid tissue of Waldeyer's ring.	52
Figure 1.12: Gut associated lymphoid tissue	55
Figure 3.1: Serum total Ig responses to Ag85B-ESAT6 after i.n. immunisation.	86
Figure 3.2: IgG1:IgG2a ratios after i.n. immunisation with Ag85B-ESAT6.....	88
Figure 3.3: Graphic representation of Ag85B-ESAT6-specific cytokine responses. ..	93
Figure 3.4: Graphic representation of Ag85B-ESAT6-specific cytokine responses. ..	94
Figure 4.1: Location and structure of the NALT	101
Figure 4.2: Origin and haematopoietic differentiation of immune cells.....	106
Figure 4.3: Schematic diagram showing an overview of DC movement and activation within the NALT and CLN 5, 24, and 72 hours after intranasal immunisation.....	111
Figure 4.4: Schematic diagram showing an overview of macrophage movement and activation within the NALT and CLN 5, 24, and 72 hours after intranasal immunisation.....	115
Figure 4.5: Schematic diagram showing an overview of NKC movement and activation within the NALT and CLN 5, 24, and 72 hours after intranasal immunisation.....	119

Figure 4.6: Schematic diagram showing an overview of neutrophil movement and activation within the NALT and CLN 5, 24, and 72 hours after intranasal immunisation.....122

Figure 4.7: Immunofluorescent analysis of NALT and CLN early after intranasal immunisation.125

Figure 4.8: Differential expression of cell adhesion molecules in the NALT and CLN after intranasal immunisation.141

Figure 4.9: Immunofluorescence evaluation of GC in both CLN and NALT from immunised Balb/c mice.154

Figure 5.1: Crosstalk between NKC and DC.162

Figure 5.2: Impact of *in vivo* administration of anti-asialo GM1 on NKC percentages in Balb/c mice.164

Figure 5.3: Percentages of macrophages and NKT cells in naïve normal IgG and anti-asialo GM1 treated mice.166

Figure 5.4: Anti-asialo GM1 antibody treatment alters the induction of antigen-specific cytokines.168

Figure 5.5: Anti-asialo GM1 treatment influences the development of antigen-specific antibody responses.172

Figure 6.1: Schematic diagram showing the construction of the plasmid used to express Ag85B-ESAT6 via the *ssaG* promoter.....190

Figure 6.2: Schematic diagram showing the construction of the plasmid used to express Ag85B-ESAT6 via the *nirB* promoter.191

Figure 6.3: Coomassie gel and western blot analysis of recombinant *Salmonella* cultures.193

Figure 6.4: Ag85B-ESAT6-specific total Ig titres in mice immunised with recombinant *in vivo* inducible *Salmonella* strains.....195

Figure 6.5: IgG1/IgG2a profile after recombinant *Salmonella* immunisation.196

Figure 6.6: Ag85B-ESAT6-specific cytokine production from splenocytes of recombinant *Salmonella* immunised animals.....198

Figure 6.7: Schematic diagram for the construction of targeting construct and chromosomal integration of expression cassette.....206

Figure 6.8: Coomassie gel and western blot analysis of recombinant chromosomal *Salmonella* construct.207

Figure 6.9: Time-course of the serum Ig anti-Ag85B-ESAT6 antibody response in mice following oral <i>Salmonella</i> prime and intranasal protein boost.....	210
Figure 6.10: Time-course of the serum IgG anti-Ag85B-ESAT6 antibody responses.	212
Figure 6.11: Day 50, 57 and 120 serum anti-Ag85B-ESAT6 IgG1:IgG2a responses.	214
Figure 6.12: Time-course of the serum IgA anti-Ag85B-ESAT6 antibody responses.	216
Figure 6.13: Mucosal IgA induced by immunisation with <i>Salmonella</i> live vector vaccine.....	218
Figure 6.14: Ag85B-ESAT6-specific cytokine responses in mice immunised with <i>Salmonella</i> live vector vaccines.	221
Figure 6.15: Bacterial burden in vaccinated mice challenged with <i>M. tuberculosis</i>	225
Figure 8.1: Scatter plots of cell populations early after intranasal immunisation.	237
Figure 8.2: Immunofluorescent analysis of NALT and CLN early after intranasal immunisation.	241
Figure 8.3: Mean Fluorescence Intensity (MFI) of activation markers on innate immune cell populations early after intranasal immunisation.	248
Figure 8.4: Differential expression of cell adhesion molecules in the NALT and CLN after intranasal immunisation.	251
Figure 8.5: Immunohistochemical evaluation of GC in both CLN and NALT from immunised Balb/c mice.	259

Abbreviations

Ag85B	Antigen 85B (30kDa mycolyl transferase)
AIDS	Acquired immunodeficiency syndrome
APC	Antigen presenting cells
bp	Base pair
BCG	Bacille Calmette-Guérin
BSA	Bovine serum albumin
BALT	Bronchial-associated lymphoid tissue
CAMs	Cell adhesion molecules
CBA	Cytometric Bead Analysis
CD	Cluster of Differentiation
CFUs	Colony forming units
CLN	Cervical lymph nodes
CMI	Cell mediated immunity
CMIS	Common mucosal immune system
conA	Concavalin A
CT-B	Cholera toxin B-subunit
CTL	Cytotoxic T lymphocyte
DC	Dendritic cells
ELISA	Enzyme-linked immunosorbant assay
ESAT-6	Early secreted antigenic target 6kDa
FACS	Fluorescence-activated cell sorting
FDC	Follicular dendritic cells
GALT	Gut-associated lymphoid tissue
GC	Germinal Centres
GM-CSF	Granulocyte-macrophage colony stimulating factor
HEV	High Endothelial Venules
HIV	Human immunodeficiency virus
HRP	Horseradish peroxidase
ICAM-1	Intracellular adhesion molecule-1
IFN	Interferon
Ig	Immunoglobulin

i.n.	Intranasal
i.p.	Intraperitoneal
i.v.	Intravenous
IL	Interleukin
kDa	Kilo Dalton
KO	Knock-out
LB	Luria Bertani
LN _s	Lymph nodes
LT	Heat-labile toxin
LT-B	LT B-subunit
LTK63	LT with mutation in A subunit (ser63→lys)
mAb	Monoclonal antibody
MAdCAM-1	Mucosal addressin cell adhesion molecule-1
MCP-1	Macrophage chemoattractant protein-1
MHC	Major histocompatibility Complex
NALT	Nasal-associated lymphoid tissue
NKC	Natural Killer cells
NKT	Natural Killer T cells
NRAMP1	Natural resistance-associated macrophage protein-1
OD	Optical density
OPD	O-Phenylenediamine dihydrochloride
p	Plasmid
PBS	Phosphate Buffered Saline
PBST	PBS + 0.01% Tween 20
PCR	Polymerase chain reaction
PP	Peyer's patches
PPD	Purified protein derivative
PNA	Peanut agglutinin
PNAd	Peripheral Node Addressin
rBCG	Recombinant BCG
RD	Region of difference
rpm	Revolutions per minute
RT	Room temperature
s.c.	Subcutaneous

TBS	Tris buffered saline
TCR	T cell receptor
TetC	Tetanus toxin fragment C
T _H	T-helper
TNF	Tumour necrosis factor
TLR	Toll-like receptor
Tween	Polyoxyethylene-sorbitan monolaurate
URT	Upper respiratory tract
VCAM-1	Vascular cell adhesion molecule-1
WHO	World Health Organisation